HemOnc Today -- There may be no relationship between the previously identified genetic variant CYP2C19*2 that affects clopidogrel response and cardiovascular outcomes, according to the results of the CHARISMA trial, presented at Transcatheter Cardiovascular Therapeutics 2009 by Deepak L. Bhatt, MD, MPH.
